[RESEARCH BLOG] · 2026-10-02
Hyperfine, Inc. (HYPR) – **BUY** Signal Amid Recovery Regime and Gulf Market Expansion
By Pierre Brunelle · Founder & Research Lead
Hyperfine closed at $0.87, a 7.41 % gain on the Thursday session of 2026‑10‑01 (as of 2026‑10‑01). The LOPJLB model has issued a BUY directional signal with a perfect Score 5 while the broader market environment is classified as a RECOVERY regime.
News / Catalysts
- 2026‑09‑28 – Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets (Business Wire)
- 2026‑09‑16 – MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award (Business Wire)
- 2026‑09‑15 – Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents (Business Wire)
- 2026‑08‑31 – Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference (Business Wire)
- 2026‑08‑26 – Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans (GuruFocus)
- 2026‑08‑20 – Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings (GuruFocus)
- 2026‑08‑07 – Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript (Seeking Alpha)
- 2026‑08‑06 – Hyperfine Q2 Earnings Call Highlights (MarketBeat)
These releases coalesce around three themes: Gulf Cooperation Council (GCC) market expansion, clinical‑trial progress that widens the Swoop® system’s indication set, and leadership recognition that underscores strategic vision.
Fundamentals and Valuation
Hyperfine’s valuation metrics reflect a company still in the investment‑stage of its lifecycle, with negative earnings but improving operating leverage.
| Metric | Value |
|---|---|
| P/E (TTM) | ‑2.28 |
| EV/EBITDA (TTM) | ‑1.34 |
| P/B | 2.37 |
| Gross Margin | 51.41 % |
| Operating Margin | ‑203.3 % |
| Net Margin | ‑210.8 % |
| ROIC | ‑60.18 % |
| ROE | ‑100.3 % |
| ROA | ‑55.32 % |
| Debt‑to‑Equity | 36.49 |
Analyst consensus assigns a Buy rating with an average price target of $2.00, implying a potential upside of roughly 130 % from the current price. The Value score of 8.00 and Growth score of 32.00 place Hyperfine firmly in the “balanced” archetype, where growth expectations are tempered by a modest valuation cushion.
Multi‑Year Financial Trajectory
Revenue has climbed steadily over the past six fiscal years, moving from $0.294 M in 2020 to $13.563 M in 2025, a compound annual growth rate (CAGR) of roughly 115 %. Earnings per share (EPS) have improved marginally, moving from ‑$0.93 in 2020 to ‑$0.43 in 2025, indicating that while the company remains loss‑making, the per‑share loss is narrowing as top‑line growth accelerates.
Margins have shown the most dramatic evolution. Gross margin swung from a deeply negative ‑162.2 % in 2020 to a healthy 49.79 % in 2025, driven by higher unit economics as the Swoop® system’s bill‑of‑materials cost declines and service contracts contribute higher‑margin revenue. Operating margin, while still negative, improved from ‑7,990 % in 2020 to ‑273.4 % in 2025, a sign that the company’s operating expense base is not expanding as rapidly as revenue. Net margin follows a similar path, moving from ‑7,944 % to ‑262.3 % over the same period.
Return metrics remain weak, with ROIC at ‑60.18 %, ROE at ‑100.3 %, and ROA at ‑55.32 %, all reflecting the company’s early‑stage status and high leverage. However, the upward trajectory in gross margin and the narrowing loss per share indicate that these return figures could improve markedly if the GCC expansion and the upcoming contrast‑enhanced indication gain regulatory approval and market adoption.
LOPJLB Signal Read
The LOPJLB engine flags HYPR with a BUY directional signal in a RECOVERY market regime, meaning the model expects the stock to benefit from the broader rebound in risk assets after a recent pullback. The composite PERF score of ‑10.90 and FUND quality score of 7.64 place the ticker in the higher‑quality segment of the universe, while the Value (8.00) and Growth (32.00) scores underline a balanced blend of attractive valuation and strong upside potential. The stock’s archetype is classified as Balanced.
For a visual overlay of the model’s technical signals, explore the interactive chart above this article, and review the full methodology at the LOPJLB methodology page.
Closing Remarks
Hyperfine’s recent expansion into the GCC, the completion of a pivotal contrast‑PMR study, and the FDA clearance of its next‑generation AI software collectively reinforce a narrative of market penetration and product differentiation. While the balance sheet remains leveraged and profitability is still distant, the company’s revenue acceleration, margin improvement, and analyst consensus target suggest a sizable upside potential.
Readers seeking deeper data, earnings transcripts, and the full suite of LOPJLB overlays should visit the dedicated stock page at https://www.lopjlb.com/stock/HYPR, explore the earnings‑specific insights at https://www.lopjlb.com/stock/HYPR/earnings.md (if applicable), and run their own scans via the LOPJLB Screener.
The information provided herein is for research purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.